8-K: BioXcel Therapeutics' SERENITY At-Home Phase 3 Trial Reaches 50% Enrollment

BioXcel Therapeutics announces that its SERENITY At-Home Phase 3 trial for BXCL501 has reached 50% enrollment as of March 20, 2025, with topline data expected in the second half of 2025.

Summary

• BioXcel Therapeutics initiated patient enrollment in the SERENITY At-Home pivotal Phase 3 trial in September 2024.
• The trial evaluates the safety of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in an at-home setting.
• As of March 20, 2025, 24 clinical trial sites have been opened and 100 patients have been enrolled, representing 50% of the total expected enrollment.
• Topline data results are expected in the second half of 2025.
• The data is intended to support a supplemental new drug application (sNDA) to potentially expand the label of IGALMI (dexmedetomidine) sublingual film.

Sentiment

Score: 7

Explanation: The announcement is positive as the trial is progressing as expected, but the ultimate success depends on the topline data and regulatory approval.

Positives

• The SERENITY At-Home Phase 3 trial is progressing as planned, reaching 50% enrollment.
• The topline data, expected in the second half of 2025, could lead to label expansion for IGALMI.

Risks

• The trial's success and the subsequent sNDA submission are subject to regulatory approval.
• The topline data may not be positive, which could impact the potential label expansion for IGALMI.

Future Outlook

The company anticipates topline data from the SERENITY At-Home trial in the second half of 2025, which will inform a potential sNDA submission for IGALMI.

Industry Context

The development of BXCL501 and the SERENITY At-Home trial address the need for effective and convenient treatments for agitation associated with bipolar disorders and schizophrenia, potentially offering a new option for patients and caregivers.

Stakeholder Impact

• Positive impact on patients and caregivers if BXCL501 proves effective and receives regulatory approval.
• Potential positive impact on shareholders if the label of IGALMI is expanded.

Next Steps

• Completion of patient enrollment in the SERENITY At-Home Phase 3 trial.
• Analysis of topline data results expected in the second half of 2025.
• Potential submission of a supplemental new drug application (sNDA) for IGALMI.

Key Dates

Keywords

BXCL501, SERENITY At-Home Trial, BioXcel Therapeutics, IGALMI, Phase 3 Trial, Agitation, Bipolar Disorder, Schizophrenia, sNDA, Dexmedetomidine